Amit Sachdev, EVP, Chief Patient Officer at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 7,875 shares at $230.00 ($1.9M) on 2020-02-25, disclosed to the SEC on 2020-02-26.
Seasonal sale ($1.9M) by EVP, Chief Patient Officer — this insider has traded VRTX in February in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $239.23 | 3,156 | $755K | 40.6% |
| 2 | $230.00 | 953 | $219K | 11.8% |
| 3 | $230.98 | 270 | $62K | 3.4% |
| 4 | $230.98 | 270 | $62K | 3.4% |
| 5 | $232.62 | 450 | $105K | 5.6% |
| 6 | $233.18 | 90 |
| $21K |
| 1.1% |
| 7 | $234.56 | 533 | $125K | 6.7% |
| 8 | $234.56 | 533 | $125K | 6.7% |
| 9 | $235.75 | 360 | $85K | 4.6% |
| 10 | $236.63 | 180 | $43K | 2.3% |
| 11 | $238.33 | 540 | $129K | 6.9% |
| 12 | $238.33 | 540 | $129K | 6.9% |
| Total | $236.13 avg | 7,875 | $1.9M | 100% |
| Filing → |
| VRTX | SELL | 2024-05-17 | $14K | — | Filing → |
| VRTX | SELL | 2024-02-27 | $2.6M | — | Filing → |
| VRTX | SELL | 2024-02-23 | $2.7M | — | Filing → |